Kamada (NASDAQ:KMDA) Issues Quarterly Earnings Results, Beats Estimates By $0.05 EPS

Kamada (NASDAQ:KMDA) issued its quarterly earnings results on Wednesday. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.11 by $0.05, FiscalAI reports. The firm had revenue of $54.92 million for the quarter, compared to analyst estimates of $50.84 million. Kamada had a return on equity of 7.73% and a net margin of 11.21%.

Here are the key takeaways from Kamada’s conference call:

• Record first-half performance: Revenue rose 13% year over year to $100.2 million, adjusted EBITDA increased 14% to $25.7 million, and net income grew 18% to $13.4 million. Second-quarter revenue and EBITDA also reached company records, with a 26% EBITDA margin.
• Kamada reiterated its 2026 guidance of $200 million–$205 million in revenue and $50 million–$53 million in adjusted EBITDA, noting that first-half results are approximately 50% of the annual midpoint and that it remains comfortable with second-half expectations.
• The company signed a three-year, $50 million normal-source plasma supply agreement, with initial commercial sales expected in the fourth quarter of 2026. Houston and San Antonio facilities are expected to provide roughly $16 million–$20 million of annual capacity, while specialty plasma will support Kamada’s own products.
• Management reported continued demand growth for KEDRAB, VARIZIG, HepaGam B and other commercial products, alongside expansion of its biosimilar distribution business in Israel and the MENA region. Kamada expects its biosimilar portfolio to generate $15 million–$20 million in annual sales within several years.
• CFO Chaime Orlev will leave the company at the end of 2026 after nine years, and Kamada has begun searching for a successor, creating a near-term executive-transition risk.

Kamada Price Performance

Kamada stock opened at $7.17 on Thursday. The company has a market cap of $412.54 million, a price-to-earnings ratio of 20.50, a price-to-earnings-growth ratio of 0.65 and a beta of 0.86. Kamada has a 12 month low of $6.50 and a 12 month high of $9.35. The stock’s 50-day moving average is $7.22 and its 200-day moving average is $7.97.

More Kamada News

Here are the key news stories impacting Kamada this week:

• Positive Sentiment: Q2 results exceeded expectations: Kamada reported adjusted earnings of $0.16 per share, above the $0.11 consensus estimate, while revenue reached $54.92 million versus expectations of $50.84 million. Kamada earnings report
• Positive Sentiment: Record growth and profitability: Kamada described the first half and second quarter of 2026 as the strongest in its history, with double-digit profitable growth. Its 11.21% net margin and 7.73% return on equity further support the improved operating performance. Kamada 2026 financial results
• Positive Sentiment: Full-year outlook reaffirmed: Management maintained its 2026 revenue guidance of approximately $200 million to $205 million, signaling continued confidence in demand for its specialty plasma-derived therapies. Kamada affirms 2026 guidance
• Neutral Sentiment: CFO succession planned: Chief Financial Officer Chaime Orlev will leave the role on December 31, 2026, after serving since 2017. Kamada has begun searching for a successor, and Orlev is expected to assist with the transition. Kamada CFO transition
• Neutral Sentiment: Short-interest data provides no signal: Reported short interest was zero shares, making the data unreliable as an indicator of potential covering or additional selling pressure.

Institutional Trading of Kamada

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Barclays PLC lifted its position in Kamada by 417.1% during the fourth quarter. Barclays PLC now owns 4,788 shares of the biotechnology company’s stock valued at $34,000 after buying an additional 3,862 shares in the last quarter. XTX Topco Ltd purchased a new position in shares of Kamada in the 4th quarter valued at $103,000. SIH Partners LLLP acquired a new position in shares of Kamada during the 4th quarter valued at $134,000. Quadrature Capital Ltd lifted its holdings in shares of Kamada by 53.5% during the 4th quarter. Quadrature Capital Ltd now owns 21,889 shares of the biotechnology company’s stock valued at $155,000 after acquiring an additional 7,627 shares in the last quarter. Finally, Man Group plc purchased a new stake in Kamada during the 3rd quarter worth $199,000. Institutional investors and hedge funds own 20.38% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the stock. Weiss Ratings lowered shares of Kamada from a “buy (b)” rating to a “buy (b-)” rating in a report on Thursday, June 25th. Benchmark reaffirmed a “buy” rating on shares of Kamada in a research report on Tuesday, July 21st. William Blair set a $15.00 price target on shares of Kamada in a research note on Tuesday, July 21st. Finally, Wall Street Zen lowered shares of Kamada from a “buy” rating to a “hold” rating in a report on Saturday, May 23rd. Three investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $13.00.

About Kamada

Kamada Ltd. is a biopharmaceutical company headquartered in Israel that specializes in the development, manufacturing and commercialization of plasma‐derived protein therapeutics. The company focuses on treatments for rare and serious diseases, leveraging its proprietary fractionation and purification technologies to produce purified human proteins. Kamada’s product portfolio addresses critical therapeutic areas in immunology, hematology and pulmonology, where alternative treatment options may be limited.

Among Kamada’s marketed products is Glassia®, an alpha‐1 antitrypsin augmentation therapy approved by the U.S.